Stephen Wall
Otolaryngology · Washington, DCNPI 1861405706
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,432 of the $3,275 with a category attached, or 74.3%. 17 manufacturers reported payments, led by Sanofi at 39.3% of the total. Reporting peaked in 2023 at $1,074 and has fallen 96.9% since, to $33 in 2025.
Across 99 payments — averaging $33.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- Stryker$636
- Optinose US, Inc.$346
- GSK$251
- Intersect ENT, Inc.$236
- Acclarent, Inc$177
- plus $339 from 11 others
What the payments were for
- Consulting fees$84326%
- Food & beverage$2,43274%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 19 | $1,288 |
| Stryker | 18 | $636 |
| Optinose US, Inc. | 20 | $346 |
| GSK | 13 | $251 |
| Intersect ENT, Inc. | 4 | $236 |
| Acclarent, Inc | 7 | $177 |
| Regeneron Healthcare Solutions, Inc. | 4 | $89 |
| Kaleo, Inc. | 3 | $49 |
| Alk-abello, Inc | 2 | $35 |
| AstraZeneca | 2 | $32 |
| USWM, LLC | 1 | $26 |
| Acelrx Pharmaceuticals, Inc. | 1 | $25 |
| Dendreon Pharmaceuticals LLC | 1 | $20 |
| Lilly USA, LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Aerin Medical Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,275 in reported general payments places this provider in the 80th percentile of 41 otolaryngology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ofloxacin | 20 | $791 |
| Mupirocin | 51 | $372 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $187 |
| Methylprednisolone | 15 | $141 |
| Doxycycline Hyclate | 14 | $96 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Washington
- Michael HoaWashington$57K
- Manish KhannaWashington$24K
- Sarah RapoportWashington$11K
- Hung KimWashington$11K
- Punam ThakkarWashington$9K
- Shaum SridharanWashington$8K
- Stanley ChiaWashington$4K
- William GaoWashington$3K
- Adedoyin KalejaiyeWashington$3K
- Mark RussoWashington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.